Cargando…

Ratio of Aβ42/P-tau(181p) in CSF is associated with aberrant default mode network in AD

The default mode network (DMN) is particularly relevant to Alzheimer's disease (AD) since its structures are vulnerable to deposition of amyloid. Decreased levels of β-amyloid(1-42) (Aβ42) and increased total tau protein (T-tau) and tau phosphorylated at position threonine 181 (P-tau(181p)) in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Xiaozhen, Li, Tie-Qiang, Andreasen, Niels, Wiberg, Maria Kristoffersen, Westman, Eric, Wahlund, Lars-Olof
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2013
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3581831/ https://www.ncbi.nlm.nih.gov/pubmed/23439248 http://dx.doi.org/10.1038/srep01339

Ejemplares similares

Plasma p‐tau181/Aβ(1‐42) ratio predicts Aβ‐PET status and correlates with CSF‐p‐tau181/Aβ(1‐42) and future cognitive decline
por: Fowler, Christopher J., et al.
Publicado: (2022)

Comparing the Clinical Utility and Diagnostic Performance of CSF P-Tau181, P-Tau217, and P-Tau231 Assays
por: Leuzy, Antoine, et al.
Publicado: (2021)

Clinical performance and head-to-head comparison of CSF p-tau235 with p-tau181, p-tau217 and p-tau231 in two memory clinic cohorts
por: Lantero-Rodriguez, Juan, et al.
Publicado: (2023)

CSF P-Tau181 and Other Biomarkers in Patients With Neuronal Intranuclear Inclusion Disease
por: Kurihara, Masanori, et al.
Publicado: (2023)

Plasma p-tau181 and p-tau217 in discriminating PART, AD and other key neuropathologies in older adults
por: Yu, Lei, et al.
Publicado: (2023)

CSF tau368/total-tau ratio reflects cognitive performance and neocortical tau better compared to p-tau181 and p-tau217 in cognitively impaired individuals
por: Simrén, Joel, et al.
Publicado: (2022)

CSF sTREM2 in delirium—relation to Alzheimer’s disease CSF biomarkers Aβ42, t-tau and p-tau
por: Henjum, Kristi, et al.
Publicado: (2018)

P‐tau/Aβ42 and Aβ42/40 ratios in CSF are equally predictive of amyloid PET status
por: Campbell, Michelle R., et al.
Publicado: (2021)

Accuracy of plasma Aβ40, Aβ42, and p-tau181 to detect CSF Alzheimer’s pathological changes in cognitively unimpaired subjects using the Lumipulse automated platform
por: Martínez-Dubarbie, Francisco, et al.
Publicado: (2023)

Clinical and analytical comparison of six Simoa assays for plasma P-tau isoforms P-tau181, P-tau217, and P-tau231
por: Bayoumy, Sherif, et al.
Publicado: (2021)

(18)F‐AV‐1451 and CSF T‐tau and P‐tau as biomarkers in Alzheimer's disease
por: Mattsson, Niklas, et al.
Publicado: (2017)

Plasma pTau181 as a biomarker for Alzheimer's disease
por: Meng, Jie, et al.
Publicado: (2020)

Gray matter network properties show distinct associations with CSF p-tau 181 levels and amyloid status in individuals without dementia
por: Luigi, Lorenzini, et al.
Publicado: (2022)

Comparing (18)F-AV-1451 with CSF t-tau and p-tau for diagnosis of Alzheimer disease
por: Mattsson, Niklas, et al.
Publicado: (2018)

No added diagnostic value of non-phosphorylated tau fraction (p-tau(rel)) in CSF as a biomarker for differential dementia diagnosis
por: Goossens, Joery, et al.
Publicado: (2017)

Comparing tau status determined via plasma pTau181, pTau231 and [(18)F]MK6240 tau-PET
por: Tissot, Cécile, et al.
Publicado: (2022)

Plasma tau complements CSF tau and P-tau in the diagnosis of Alzheimer's disease
por: Fossati, Silvia, et al.
Publicado: (2019)

Cerebrospinal Fluid P-Tau(181P): Biomarker for Improved Differential Dementia Diagnosis
por: Struyfs, Hanne, et al.
Publicado: (2015)

Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer’s disease
por: Janelidze, Shorena, et al.
Publicado: (2020)

Atrophy of the Posterior Subiculum Is Associated with Memory Impairment, Tau- and Aβ Pathology in Non-demented Individuals
por: Lindberg, Olof, et al.
Publicado: (2017)

Meta-Review of CSF Core Biomarkers in Alzheimer’s Disease: The State-of-the-Art after the New Revised Diagnostic Criteria
por: Ferreira, Daniel, et al.
Publicado: (2014)

CSF p-Tau levels in the prediction of Alzheimer's disease
por: Kandimalla, Ramesh J. L., et al.
Publicado: (2013)

Cortical microstructural associations with CSF amyloid and pTau
por: Nir, Talia M., et al.
Publicado: (2023)

CSF P-tau 231 as Biomarker in Alzheimer's Disease
por: Mukherjee, Adreesh, et al.
Publicado: (2022)

Predicting clinical decline and conversion to Alzheimer’s disease or dementia using novel Elecsys Aβ(1–42), pTau and tTau CSF immunoassays
por: Blennow, Kaj, et al.
Publicado: (2019)

MRI Markers of Small Vessel Disease and the APOE Allele in Cognitive Impairment
por: Shams, Mana, et al.
Publicado: (2022)

Longitudinal tau and metabolic PET imaging in relation to novel CSF tau measures in Alzheimer’s disease
por: Leuzy, Antoine, et al.
Publicado: (2019)

Association of plasma P-tau181 with memory decline in non-demented adults
por: Therriault, Joseph, et al.
Publicado: (2021)

Lysophosphatidylcholines are associated with P-tau181 levels in early stages of Alzheimer’s Disease
por: Kalia, Vrinda, et al.
Publicado: (2023)

Tau PET correlates with different Alzheimer’s disease‐related features compared to CSF and plasma p‐tau biomarkers
por: Ossenkoppele, Rik, et al.
Publicado: (2021)

Differential roles of Aβ42/40, p-tau231 and p-tau217 for Alzheimer’s trial selection and disease monitoring
por: Ashton, Nicholas J., et al.
Publicado: (2022)

Associations of longitudinal plasma p-tau181 and NfL with tau-PET, Aβ-PET and cognition
por: Rauchmann, Boris Stephan, et al.
Publicado: (2021)

CSF nonphosphorylated Tau as a biomarker for the discrimination of AD from CJD
por: Ermann, Natalia, et al.
Publicado: (2018)

Diagnostic Utility of CSF Tau and Aβ (42) in Dementia: A Meta-Analysis
por: Agarwal, Rachna, et al.
Publicado: (2011)

CSF Potential Biomarkers Aβ42 and Tau: associations of Apo E Genotype
por: Kandimalla, Ramesh, et al.
Publicado: (2010)

Head‐to‐head comparison of clinical performance of CSF phospho‐tau T181 and T217 biomarkers for Alzheimer's disease diagnosis
por: Karikari, Thomas K., et al.
Publicado: (2020)

Detection of Alzheimer's disease amyloid beta 1‐42, p‐tau, and t‐tau assays
por: van Harten, Argonde C., et al.
Publicado: (2021)

Plasma pTau181 predicts cortical brain atrophy in aging and Alzheimer’s disease
por: Tissot, Cécile, et al.
Publicado: (2021)

Plasma p-tau181, neurofilament light chain and association with cognition in Parkinson’s disease
por: Batzu, Lucia, et al.
Publicado: (2022)

Plasma p‐tau181, p‐tau217, and other blood‐based Alzheimer's disease biomarkers in a multi‐ethnic, community study
por: Brickman, Adam M., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_v2emh4p7kf6unf4cledk28eslj